Tivozanib for the treatment of advanced renal cell carcinoma

Chatzkel, J; Ramnaraign, B; Sonpavde, G

Sonpavde, G (通讯作者),Dana Farber Canc Inst, Harvard Med Sch, 450 Brookline Ave,D-924, Boston, MA 02215 USA.

EXPERT OPINION ON PHARMACOTHERAPY, 2022; 23 (10): 1135

Abstract

Introduction: Renal cell carcinoma (RCC) accounts for 2.4% of cancers, with clear cell kidney cancer being the most common histologic subtype. Despite......

Full Text Link